Aaron J. Scott
Expertise in
18
conditions

Dr. Aaron J. Scott

Oncology
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
Accepting New Patients
Offers Telehealth
Referral may be required
Before you request
Expertise in
18
conditions
3838 North Campbell Avenue, Building 1, 
Tucson, AZ 

Overview

I enjoy advancing medicine through academics and excellent patient care.My particular interests are in clinical trial development and laboratory research investigating new agents to improve outcomes in patients with GI cancers.

Dr. Scott is highly rated in 18 conditions, according to our data. His clinical expertise encompasses Colorectal Cancer, Pancreatic Cancer, Lynch Syndrome, Neuroendocrine Tumor, and Bone Marrow Aspiration.

Dr. Scott is board certified in American Board Of Internal Medicine/Medical Oncology and American Board Of Internal Medicine. He is actively involved in clinical research, co-authoring 70 peer reviewed articles and participating in 17 clinical trials. Dr. Scott is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in AZ

Board Certifications

American Board Of Internal Medicine/Medical Oncology
American Board Of Internal Medicine

Fellowships

University Of Colorado At Denver, Hematology/Oncology, 2016

Hospital Affiliations

Banner - University Medical Center Tucson
Banner - University Medical Center Tucson Campus
Banner-University Medical Center South Campus

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Highmark
  • EPO
  • HMO
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Medicare
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE PART D
MercyCare
  • EPO
  • HMO
Northern Plains Alliance
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE PDP
Oscar
  • EPO
  • HMO
  • PPO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
VibrantRx
  • MEDICARE PDP
  • OTHER MEDICARE
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 15 Less Insurance Carriers -

Locations

University of Arizona Cancer Center
3838 North Campbell Avenue, Building 1, Tucson, AZ 85719
Other Locations
University of Arizona Cancer Center
1891 West Orange Grove Road, Building 1, Tucson, AZ 85704

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

17 Clinical Trials

A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
A Phase II Study (With Safety run-in) of Evorpacept (ALX148) in Combination With Cetuximab and Pembrolizumab in Patients With Refractory Microsatellite Stable Metastatic Colorectal Cancer
Enrollment Status: Terminated
Publish Date: September 03, 2026
Intervention Type: Drug
Study Drugs: ALX148, Cetuximab, Pembrolizumab
Study Phase: Phase 2
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Randomized Trial of Standard Chemotherapy Alone or Combined With Atezolizumab as Adjuvant Therapy for Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Other, Procedure, Drug
Study Drugs: Atezolizumab, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 3
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
A Phase 2 Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab for the Treatment of Poorly Differentiated Neuroendocrine Carcinomas
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2026
Intervention Type: Biological, Drug
Study Drugs: Cabozantinib S-malate, Ipilimumab, Nivolumab
Study Phase: Phase 2
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
A Phase IIB Clinical Trial of the Multitargeted Recombinant Adenovirus 5 (CEA/MUC1/Brachyury) Vaccines (TRI-AD5) and IL-15 Superagonist N-803 in Lynch Syndrome
Enrollment Status: Active_not_recruiting
Publish Date: June 17, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Phase: Phase 2
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Phase II Trial Evaluating the Safety and Efficacy of Atezolizumab in Combination With Cabozantinib for the Treatment of Metastatic, Refractory Pancreatic Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 02, 2026
Intervention Type: Drug
Study Drug: Cabozantinib+Atezolizumab
Study Phase: Phase 2
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
A Phase 2b, Open-label, Single-arm Study of ZW25 Monotherapy in Subjects With Advanced or Metastatic HER2-amplified Biliary Tract Cancers
Enrollment Status: Completed
Publish Date: September 15, 2025
Intervention Type: Drug
Study Drug: ZW25 (Zanidatamab)
Study Phase: Phase 2
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Perioperative Therapy for Resectable Pancreatic Adenocarcinoma and Borderline Resectable Pancreatic Adenocarcinoma With Molecular Correlates
Enrollment Status: Completed
Publish Date: July 01, 2025
Intervention Type: Drug
Study Drugs: Nab-paclitaxel, Gemcitabine
Study Phase: Phase 2
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Prospective, Multicenter, Randomized, Controlled Study Evaluating SIR-Spheres Y-90 Resin Microspheres Preceding Cisplatin-gemcitabine (CIS-GEM) Chemotherapy Versus CIS-GEM Chemotherapy Alone as First-line Treatment of Patients With Unresectable Intrahepatic Cholangiocarcinoma
Enrollment Status: Terminated
Publish Date: May 09, 2025
Intervention Type: Device, Drug
Study Drug: Cisplatin-Gemcitabine
Study Phase: Phase 2/Phase 3
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Phase II/III Study of Circulating Tumor DNA as a Predictive Biomarker in Adjuvant Chemotherapy in Patients With Stage IIA Colon Cancer (COBRA)
Enrollment Status: Active_not_recruiting
Publish Date: May 07, 2025
Intervention Type: Drug, Other
Study Drugs: Capecitabine, 5-Fluorouracil, Leucovorin, Oxaliplatin
Study Phase: Phase 2/Phase 3
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase 2/3 Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)
Enrollment Status: Completed
Publish Date: January 22, 2025
Intervention Type: Drug, Other
Study Drugs: Tucatinib, Trastuzumab, Ramucirumab, Paclitaxel
Study Phase: Phase 2/Phase 3
View 9 Less Clinical Trials

70 Total Publications

Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.
Activation of the endocytosis pathway stratifies subtypes and therapeutic sensitivity in colorectal cancer.
Journal: Research square
Published: July 10, 2026
Similar Doctors
Expertise in
11
conditions
Expertise in
11
conditions
Referral may be required
Before you request

Banner-University Medical Center Tucson Campus

1625 North Campbell Avenue, 
Tucson, AZ 
 (0.3 miles away)
520-694-0111
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

I enjoy traveling, dancing and food. Dr. Shroff is highly rated in 11 conditions, according to our data. Her clinical expertise encompasses Cholangiocarcinoma (Bile Duct Cancer), Pancreatic Cancer, Gallbladder Cancer, Pancreaticoduodenectomy, and Pancreatectomy. Dr. Shroff is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Shroff is currently accepting new patients.

Expertise in
25
conditions
Expertise in
25
conditions
Referral may be required
Before you request

University Of Arizona Cancer Center

3838 North Campbell Avenue, Building 1, 
Tucson, AZ 
 (0.1 miles away)
520-694-2873
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Linda Garland is an Oncologist practicing medicine in Tucson, Arizona. Dr. Garland is highly rated in 25 conditions, according to our data. Her clinical expertise encompasses Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC), and Pleuropulmonary Blastoma. Dr. Garland is board certified in American Board Of Internal Medicine/Medical Oncology. Dr. Garland is currently accepting new patients.

Expertise in
28
conditions
Expertise in
28
conditions
Referral may be required

TMc Health Cancer Center-Wilmot, Medical Oncology, Hematology & Gynecologic Oncology

603 N Wilmot Rd # 151, 
Tucson, AZ 
 (5.4 miles away)
520-420-2560
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Joseph Buscema is an Oncologist practicing medicine in Tucson, Arizona. Dr. Buscema is highly rated in 28 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, and Testicular Yolk Sac Tumor. Dr. Buscema is currently accepting new patients.

Frequently Asked Questions about Dr. Aaron J. Scott

How do I make an appointment with Dr. Aaron J. Scott?

You can book an appointment with Dr. Aaron J. Scott by calling their office at 520-694-2873. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Aaron J. Scott a top-rated expert for Colorectal Cancer?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Aaron J. Scott is classified as an Elite expert for Colorectal Cancer, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Aaron J. Scott specialize in?

While Dr. Aaron J. Scott is a Oncology, they have specific expertise in Colorectal Cancer, Pancreatic Cancer, and Lynch Syndrome. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. Aaron J. Scott participate in research or clinical trials?

Yes. Dr. Aaron J. Scott has published 70 articles and abstracts on conditions like Colorectal Cancer. You can view a list of Dr. Aaron J. Scott's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Aaron J. Scott accept my insurance?

Dr. Aaron J. Scott accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 520-694-2873 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Scott's expertise for a condition
ConditionClose
View All 10 Distinguished Conditions
View All 7 Advanced Conditions
View All 20 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile